Sorrento Therapeutics (SRNE) – StreetInsider.com Reports
-
Oramed Pharma (ORMP) Announces $101.88M Short-Term Senior Secured Note Transaction with Scilex Holding Company
-
Sorrento Therapeutics (SRNEQ) Announces $4.6M US Government Contract From the NIAID
-
Sorrento's (SRNEQ) Bankruptcy Court Orders Brokerage Firms to Credit Dividended Scilex Stock to Customers' Accounts and Sorrento Advises Holders of Dividended Scilex Stock to Contact Brokerage Firms t
-
Scilex (SCLX) Enters Master Distributor Agreement with CH Trading Group LLC and AD Ports Group for the Distribution of ZTlido in the Middle East and North Africa Region
-
Sorrento's (SRNEQ) Bankruptcy Court Requires Brokerages to Provide Information Related to Scilex Common Stock
-
Scilex Holding Company (SCLX) and CH Trading Group Announce Territory Distribution Agreement
-
Scilex Holding Company (SCLX) Announces Commercial Launch of ELYXYBTM
-
Sorrento Therapeutics (SRNE) Granted Court Approval for $75M Financing in Chapter 11 Case
-
Sorrento Therapeutics (SRNE) Receives Court Approval for "First Day" Employee Wages and Cash Management Motions
-
Dawson James Downgrades Sorrento Therapeutics (SRNE) to Neutral
-
Sorrento Therapeutics (SRNE) commences voluntary proceedings under Chapter 11 of the United States Bankruptcy Code
-
Sorrento (SRNE) Releases Positive Results from Phase 1b Study in China in COVID-19 Patients, Ready for Pivotal Phase 3 trials with OVYDSO
-
Sorrento Therapeutics (SRNE) arbitrator awarded $125M damages to company
-
Sorrento Therapeutics (SRNE) Received FDA Clearance to Initiate Trial of Next Generation Covid Vaccine
-
Sorrento Therapeutics (SRNE) Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology
-
Sorrento (SRNE) Releases Positive Topline Results from Phase I Study Completed in Australia and Preliminary Results from Phase Ib Study in China with STI-1558
-
UPDATE: Cantor Fitzgerald Starts Sorrento Therapeutics (SRNE) at Overweight
-
Sorrento's (SRNE) Scilex and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement
-
Sorrento (SRNE) Announces Publication of Data in Cell Press Journal Med Describing Discovery and Preclinical Efficacy of a Broadly-Acting SARS-CoV-2 Neutralizing Antibody Administered IV (STI-9167) or
-
Sorrento Therapeutics (SRNE) Announces Publication in Nature Journal Scientific Reports the Details of the Discovery of SARS-CoV-2 Neutralizing Antibodies from the G-MAB Library
-
Sorrento Therapeutics (SRNE) Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept
-
Sorrento's (SRNE) Scilex Granted FDA Fast Track Designation for SP-103
-
Sorrento Therapeutics (SRNE) Announces China NMPA IND Clearance of STI-1558, An Oral Mpro Inhibitor for Phase I Trial In COVID-19 Patients
-
Sorrento Therapeutics (SRNE) PT Lowered to $5 at Dawson James
-
Sorrento Therapeutics (SRNE) Completes Successfully SAD Study, Initiates MAD Phase 1 Study with STI-1558
-
Sorrento Therapeutics (SRNE) Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19
-
Sorrento's (SRNE) Scilex to Acquire Ancora Medical
-
Sorrento's (SRNE) Scilex enters pact for exclusive license with ROMEG Therapeutics, LLC, for right to commercialize Gloperba
-
Sorrento Therapeutics (SRNE) Doses First Subject in Phase I Trial of STI-1558
-
Scilex Holding Company, a Sorrento Company (SRNE), Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes
-
Sorrento Therapeutics (SRNE) and Caris Life Collaborate to Advance Precision Medicine Development Using Comprehensive Genomic Profiling
-
Sorrento's (SRNE) Levena and Sichuan Kelun-Biotech Present Positive Clinical Progress of A166
-
Sorrento's (SRNE) Scilex to Initiate Phase 2 Study of SP-103
-
Sorrento Therapeutics (SRNE) Appoints Tammy Reilly to its Board
-
Sorrento's (SRNE) Partner Lee’s Pharm Announces Full Enrollment in Phase III Trial of Socazolimab
-
Sorrento Therapeutics (SRNE) Granted FDA Authorization to Proceed With Phase 2 Study of Abivertinib
-
Sorrento Therapeutics' (SRNE) Scilex and Vickers Vantage Corp. I (VCKA) File S-4 Registration Statement for Proposed Merger
-
Sorrento Therapeutics' (SRNE) Scilex Highlights Safety Data From Phase 1 Trial of SP-104
-
Sorrento's (SRNE) Levena Biopharma Announces Positive Clinical Data for A166
-
Sorrento Therapeutics (SRNE) Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD™ IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern
-
Sorrento's (SRNE) Scilex Holding Company Expands Direct Distribution Network to National And Regional Wholesalers And Pharmacies
-
Sorrento Therapeutics (SRNE) Announces FDA Authorization to Proceed with Phase 1 Study of Intravenous STI-9167
-
Sorrento's (SRNE) Scilex Appoints Laura Hamill to its Board
-
Sorrento Therapeutics' (SRNE) Scilex Reports March 2022 Prelim ZTlido Sales of $8.1M, $18.4M For Q1 2022
-
Sorrento Therapeutics (SRNE) Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients With Severe Pneumonia Due to COVID-19
-
Sorrento's (SRNE) Scilex Holding Company Enters Non-Binding Term Sheet for $5B Committed Equity Financing Facility, Effective Upon Close of Merger with Vickers Vantage
-
Sorrento Therapeutics (SRNE) Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Potent Neutralizing Antibodies and Protection Against Omicron (BA.1 and BA.2) and De
-
Sorrento's (SRNE) Scilex Reports Final Results for SP-102 Phase 3 Trial
-
Scilex Holding Company, a Majority-Owned Subsidiary of Sorrento (SRNE), to Become Publicly Traded Through a Merger With Vickers Vantage Corp. I (VCKA)
-
Dawson James Reiterates Sorrento Therapeutics (SRNE) at Buy, $16 PT, Sees 70% Chance of Success of Company's COVID Tests and Therapeutics
Back to SRNE Stock Lookup
